{"nctId":"NCT01999218","briefTitle":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","startDateStruct":{"date":"2013-12-16","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":1326,"armGroups":[{"label":"Ertugliflozin 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ertugliflozin 5 mg","Drug: Placebo to Ertugliflozin","Drug: Placebo to Glimepiride","Drug: Metformin","Drug: Sitagliptin"]},{"label":"Ertugliflozin 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ertugliflozin 5 mg","Drug: Ertugliflozin 10 mg","Drug: Placebo to Glimepiride","Drug: Metformin","Drug: Sitagliptin"]},{"label":"Glimepiride up to 8 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glimerpiride","Drug: Placebo to Ertugliflozin","Drug: Metformin","Drug: Sitagliptin"]}],"interventions":[{"name":"Ertugliflozin 5 mg","otherNames":["MK-8835"]},{"name":"Ertugliflozin 10 mg","otherNames":["MK-8355"]},{"name":"Glimerpiride","otherNames":[]},{"name":"Placebo to Ertugliflozin","otherNames":[]},{"name":"Placebo to Glimepiride","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Sitagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of T2DM in accordance to American Diabetes Association guidelines\n* On metformin monotherapy or metformin in combination with a single allowable anti-hyperglycemic agent (AHA), DPP-4 inhibitors, meglitinides and AGIs are listed as allowable AHAs along with sulfonylureas prior to study participation.\n* Body Mass Index (BMI) ≥18.0 kg/m\\^2\n* Male or female not of reproductive potential\n* If a female of reproductive potential, agree to remain abstinent or to use (or have their partner use) 2 acceptable combinations of birth control while participating in the trial and for 14 days after the last use of study drug.\n\nExclusion Criteria:\n\n* History or presence of type 1 diabetes mellitus or a history of ketoacidosis\n* History of other specific types of diabetes (eg, genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).\n* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor\n* Use of the following prohibited therapeutic agents within 12 weeks of study participation: insulin, injectable anti-hyperglycemic agents, pioglitazone or rosiglitazone, another SGLT2 inhibitor, bromocriptine (Cycloset®), colesevelam (Welchol®), and any other non-approved anti-hyperglycemic therapy\n* Known hypersensitivity or intolerance to metformin or glimepiride\n* On a weight-loss program or medication or medication associated with weight changes and is not weight-stable (\\>=5% change in body weight in the last 6 months)\n* History of bariatric surgery less than 12 months prior to study participation\n* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation\n* Active, obstructive uropathy or an indwelling urinary catheter\n* A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer\n* Known history of Human Immunodeficiency Virus (HIV)\n* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells\n* A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or symptomatic gallbladder disease\n* Any clinically significant malabsorption condition\n* Being treated for hyperthyroidism, or on thyroid replacement therapy that has not been at a stable dose for at least 6 weeks prior to study participation\n* Previous randomization in a study with ertugliflozin\n* Participation in other studies involving investigational drug(s) within 30 days of study participation and/or during the pre-randomization period\n* A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial\n* A positive urine pregnancy test\n* Pregnant or breast-feeding, or expecting to conceive during the trial, including 14 days following the last dose of study drug\n* Undergoing hormonal therapy in preparation to donate eggs during the period of the trial, including 14 days following the last dose of study drug\n* Consumption of more than 2 alcoholic drinks per day or engages in binge drinking\n* Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach","description":"A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":null},{"groupId":"OG001","value":"-0.64","spread":null},{"groupId":"OG002","value":"-0.74","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":null},{"groupId":"OG001","value":"71.3","spread":null},{"groupId":"OG002","value":"69.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach","description":"Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"5.2","spread":null},{"groupId":"OG002","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach","description":"This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.96","spread":null},{"groupId":"OG001","value":"-3.38","spread":null},{"groupId":"OG002","value":"0.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach","description":"This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.25","spread":null},{"groupId":"OG001","value":"-3.81","spread":null},{"groupId":"OG002","value":"0.95","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":445},"commonTop":["Hypoglycaemia","Urinary tract infection","Headache","Common cold","Upper respiratory tract infection"]}}}